See ratings and reviews when you sign up for an account.

A Randomised Clinical Trial of the Effect of Interleukin-1 Receptor Antagonism on the Insulin Production in Patients With New Onset Type 1 Diabetes

This study is currently Recruiting

December 2009 By Steno Diabetes Center

First Recieved on July 3, 2008

Last Updated on August 2, 2010

Sponsor: Steno Diabetes Center
Collaborators: Juvenile Diabetes Research Foundation
Information provided by: Steno Diabetes Center
Identifier: NCT00711503


A draw trial of the effect of Interleukin-1 Receptor Antagonist (anakinra, Kineret?) on the insulin production in patients with new onset Type 1 diabetes. Kineret? is already being used in the treatment of patients suffering from rheumatoid arthritis and preclinical studies are now suggesting that it may also be useful for patients with Type 1 diabetes. The active substance in Kineret is interleukin-1 receptor antagonist, a blocker of an immune-signal molecule named interleukin-1. The trial is a blinded randomised trial, in which the patient is allocated to receive the active drug (Kineret?) or placebo (saline). The hypothesis is that anti-IL-1 treatment as add-on therapy to conventional insulin therapy will preserve or enhance beta-cell function.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - Type 1 diabetes diagnosed according to WHO 1999 criteria - Positive GAD auto-antibodies - Age 18-35 yrs at onset of diabetes - Time from first symptoms of diabetes < 12 weeks - Peak C-peptide more than or equal to 200 pM after a standardized mixed meal test (Boost) at a test carried out when the subject is metabolically stable, i.e. after resolution of any polyuria, polydypsia or ketoacidosis. Exclusion Criteria: - Severe liver or renal disease (creatinine > 100 ?mol/L, ASAT/ALAT > 2* ULN, alkaline phosphatase > 2 * ULN) - History of heart disease, signs of cardiac failure or abnormal ECG - Present or previous malignancy - Pregnancy or failure of fertile female to comply with contraceptional planning, or breast-feeding. (Safe contraceptive methods include birth control pills, IUD, and gestagen implants) . Plans of pregnancy within 2 years. - Participation in other clinical intervention studies - Anti-inflammatory therapy (except aspirin ? 100 mg/d) - Active infections (CRP>30), history of recurrent infection or predisposition to infections - Neutropenia: ANC < 1.5*109/L, or anaemia: Haemoglobin < 8.0 g/dL - Immune-suppressive treatment or immune-deficiency - Presence at diagnosis of late diabetic complications - Concurrent vaccination with live vaccine. Known need for live vaccinations within 2 years. - Use of Etanercept within 6 months before screening or during the double-blinded study period - Hypersensitivity to E. coli-derived proteins, anakinra or any components of the product.


  • Investigator: Thomas R Mandrup-Poulsen, MD, DMSc - Principal Investigator - Steno Diabetes Center
  • Investigator: Marc Donath - Study Director - Universtity of Z?rich
  • Investigator: Flemming Pociot, DMSc - Study Director - Steno Diabetes Center
  • Investigator: Charles Dinarello - Study Director - University of Colorado Health Science Center
  • Investigator: Edwin Gale, Professor - Study Chair - Bristol University, UK


  • Aalborg Hospital

    Aalborg, 9100 Denmark

  • Aarhus Universitetshospital

    Aarhus, 8000 C Denmark

  • Bispebjerg Universitetshospital

    Copenhagen, 2400 NV Denmark

  • Steno Diabetes Center

    Gentofte, 2820 Denmark

  • Nordsj?llands Hospital, Hiller?d

    Hiller?d, 3400 Denmark

  • Ulm University, Dept. of Internal Medicine

    Ulm, Donau 89081 Germany

  • Leibniz Center for Diabetes research, Heinrich-Heine University

    Duesseldorf, 40225 Germany

  • University of Frankfurt am Main

    Frankfurt am Main, 60590 Germany

  • Institut f?r Diabetesforschung, Munich University of Technology

    Munich, 80804 Germany

  • University Campus Bio-Medico

    Rome, 00128 Italy

  • Leiden University Medical Center

    Leiden, 2300 RC Netherlands

  • Medical University of Bialystok

    Bialystok, 15-269 Poland

  • Hospital de Cruces, Diabetes Research Group

    Barakaldo, Bizkaia 48903 Spain

  • Hospital Unversitario Insular de Gran Canaria

    Las Palmas, Gran Canaria 35016 Spain

  • Hospital Santa Creu i Sant Pau

    Barcelona, 08025 Spain

  • Hospital Arnua de Vilanova

    Lleida, 25198 Spain

  • University Hospital Z?rich

    Z?rich, CH-8091 Switzerland

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.